Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
NPCE
vs
S&P 500
NPCE
S&P 500
Over the past 12 months, NPCE has outperformed S&P 500, delivering a return of +18% compared to S&P 500's +17% growth.
Stocks Performance
NPCE vs S&P 500
Performance Gap
NPCE vs S&P 500
Performance By Year
NPCE vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Neuropace Inc
Glance View
NeuroPace makes an implanted brain-stimulation device called the RNS System for people with epilepsy whose seizures are not controlled well by medication. The system sits under the scalp and connects to leads placed in the brain, where it detects seizure activity and sends small electrical pulses to interrupt it. The company’s core product is this therapy system, along with the software and support doctors use to program and monitor it. Its main customers are epilepsy centers, neurosurgeons, and hospitals that treat patients with hard-to-control focal epilepsy. NeuroPace does not sell a consumer product; it sells a specialized medical device and related clinical support to physicians who evaluate patients, implant the system, and manage follow-up care. The company makes money mainly when a device is implanted and through ongoing sales of parts, services, and system-related support. What makes NeuroPace different is that it sits at the intersection of neurology, surgery, and long-term patient management. Instead of offering a one-time treatment, it provides a closed-loop therapy that records brain activity and responds in real time. That makes the company a focused player in the epilepsy care market, with its value tied to how well doctors adopt the RNS System for patients who need more than medication.